Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 716

1.

Replacing Saturated Fat With Unsaturated Fat in Western Diet Reduces Foamy Monocytes and Atherosclerosis in Male Ldlr-/- Mice.

Lian Z, Perrard XD, Peng X, Raya JL, Hernandez AA, Johnson CG, Lagor WR, Pownall HJ, Hoogeveen RC, Simon SI, Sacks FM, Ballantyne CM, Wu H.

Arterioscler Thromb Vasc Biol. 2019 Oct 17:ATVBAHA119313078. doi: 10.1161/ATVBAHA.119.313078. [Epub ahead of print]

PMID:
31619061
2.

Preventive Cardiology as a Subspecialty of Cardiovascular Medicine: JACC Council Perspectives.

Shapiro MD, Maron DJ, Morris PB, Kosiborod M, Sandesara PB, Virani SS, Khera A, Ballantyne CM, Baum SJ, Sperling LS, Bhatt DL, Fazio S.

J Am Coll Cardiol. 2019 Oct 15;74(15):1926-1942. doi: 10.1016/j.jacc.2019.08.1016. Review.

PMID:
31601373
3.

Reply: Ischemic Event Reduction and Triglycerides.

Bhatt DL, Steg PG, Miller M, Juliano RA, Ballantyne CM.

J Am Coll Cardiol. 2019 Oct 8;74(14):1849-1850. doi: 10.1016/j.jacc.2019.08.007. No abstract available.

PMID:
31582151
4.

The use of structured data elements to identify ASCVD patients with statin-associated side effects: Insights from the Department of Veterans Affairs.

Virani SS, Akeroyd JM, Ahmed ST, Krittanawong C, Martin LA, Slagle J, Gobbel GT, Matheny ME, Ballantyne CM, Petersen LA.

J Clin Lipidol. 2019 Aug 9. pii: S1933-2874(19)30266-1. doi: 10.1016/j.jacl.2019.08.002. [Epub ahead of print]

PMID:
31501043
5.

Subclinical Cardiovascular Disease and Fall Risk in Older Adults: Results From the Atherosclerosis Risk in Communities Study.

Juraschek SP, Daya N, Appel LJ, Miller ER 3rd, Matsushita K, Michos ED, Windham BG, Ballantyne CM, Selvin E.

J Am Geriatr Soc. 2019 Sep;67(9):1795-1802. doi: 10.1111/jgs.16041. Epub 2019 Jul 10.

PMID:
31493355
6.

Association Between Circulating Troponin Concentrations, Left Ventricular Systolic and Diastolic Functions, and Incident Heart Failure in Older Adults.

Myhre PL, Claggett B, Ballantyne CM, Selvin E, Røsjø H, Omland T, Solomon SD, Skali H, Shah AM.

JAMA Cardiol. 2019 Sep 4. doi: 10.1001/jamacardio.2019.3113. [Epub ahead of print]

PMID:
31483438
7.

Circulating Monocyte Chemoattractant Protein-1 and Risk of Stroke: Meta-Analysis of Population-Based Studies Involving 17 180 Individuals.

Georgakis MK, Malik R, Björkbacka H, Pana TA, Demissie S, Ayers C, Elhadad MA, Fornage M, Beiser AS, Benjamin EJ, Boekholdt MS, Engström G, Herder C, Hoogeveen RC, Koenig W, Melander O, Orho-Melander M, Schiopu A, Söderholm M, Wareham N, Ballantyne CM, Peters A, Seshadri S, Myint PK, Nilsson J, de Lemos JA, Dichgans M.

Circ Res. 2019 Sep 27;125(8):773-782. doi: 10.1161/CIRCRESAHA.119.315380. Epub 2019 Sep 3.

PMID:
31476962
8.

Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles.

Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Jiao L, Tardif JC, Gregson J, Pocock SJ, Ballantyne CM; REDUCE-IT Investigators.

J Am Coll Cardiol. 2019 Aug 27;74(8):1159-1161. doi: 10.1016/j.jacc.2019.06.043. No abstract available.

9.

Premorbid levels of high-sensitivity cardiac troponin T and natriuretic peptide and prognosis after incident myocardial infarction.

Mok Y, Sang Y, Ballew SH, Hoogeveen RC, Ballantyne CM, Rosamond W, Coresh J, Selvin E, Matsushita K.

Am Heart J. 2019 Jul 13;216:62-73. doi: 10.1016/j.ahj.2019.07.002. [Epub ahead of print]

PMID:
31404723
10.

Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018 AHA/ACC Cholesterol Guidelines.

Virani SS, Akeroyd JM, Smith SC Jr, Al-Mallah M, Maddox TM, Morris PB, Petersen LA, Ballantyne CM, Grundy SM, Stone NJ.

J Am Coll Cardiol. 2019 Aug 6;74(5):712-714. doi: 10.1016/j.jacc.2019.05.051. No abstract available.

PMID:
31370962
11.

Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.

Ballantyne CM, Laufs U, Ray KK, Leiter LA, Bays HE, Goldberg AC, Stroes ES, MacDougall D, Zhao X, Catapano AL.

Eur J Prev Cardiol. 2019 Jul 29:2047487319864671. doi: 10.1177/2047487319864671. [Epub ahead of print]

12.

Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides.

Vijayaraghavan K, Szerlip HM, Ballantyne CM, Bays HE, Philip S, Doyle RT Jr, Juliano RA, Granowitz C.

Postgrad Med. 2019 Jul 25:1-7. doi: 10.1080/00325481.2019.1643633. [Epub ahead of print]

PMID:
31306043
13.

Seven Metrics That Will Determine Your Cardiovascular Success or Failure.

Ballantyne CM, Nambi V.

JACC Heart Fail. 2019 Aug;7(8):648-650. doi: 10.1016/j.jchf.2019.04.008. Epub 2019 Jul 10. No abstract available.

PMID:
31302041
14.

Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study).

Miller M, Ballantyne CM, Bays HE, Granowitz C, Doyle RT Jr, Juliano RA, Philip S.

Am J Cardiol. 2019 Sep 1;124(5):696-701. doi: 10.1016/j.amjcard.2019.05.057. Epub 2019 Jun 6.

15.

Lipoprotein(a) and Risk for Stroke and Myocardial Infarction: Why Aren't We Screening?

Ballantyne CM.

J Am Coll Cardiol. 2019 Jul 9;74(1):67-69. doi: 10.1016/j.jacc.2019.05.029. No abstract available.

PMID:
31272553
16.

Statin use in carnitine palmitoyltransferase II deficiency.

Saeed A, Hadley TD, Jia X, Ballantyne CM.

J Clin Lipidol. 2019 Jul - Aug;13(4):550-553. doi: 10.1016/j.jacl.2019.05.001. Epub 2019 May 10. No abstract available.

PMID:
31235404
17.

Use of Guideline-Recommended Risk Reduction Strategies Among Patients With Diabetes and Atherosclerotic Cardiovascular Disease.

Arnold SV, de Lemos JA, Rosenson RS, Ballantyne CM, Liu Y, Mues KE, Alam S, Elliott-Davey M, Bhatt DL, Cannon CP, Kosiborod M; GOULD Investigators.

Circulation. 2019 Aug 13;140(7):618-620. doi: 10.1161/CIRCULATIONAHA.119.041730. Epub 2019 Jun 7. No abstract available.

PMID:
31174429
18.

Association Between Lipid Testing and Statin Adherence in the Veterans Affairs Health System.

Jia X, Al Rifai M, Ramsey DJ, Ahmed ST, Akeroyd JM, Nambi V, Ballantyne CM, Petersen LA, Stone NJ, Virani SS.

Am J Med. 2019 Sep;132(9):e693-e700. doi: 10.1016/j.amjmed.2019.04.002. Epub 2019 May 17.

PMID:
31103643
19.

Metabolomic Pattern Predicts Incident Coronary Heart Disease.

Wang Z, Zhu C, Nambi V, Morrison AC, Folsom AR, Ballantyne CM, Boerwinkle E, Yu B.

Arterioscler Thromb Vasc Biol. 2019 Jul;39(7):1475-1482. doi: 10.1161/ATVBAHA.118.312236. Epub 2019 May 16.

PMID:
31092011
20.

Relation of Isolated Systolic Hypertension and Pulse Pressure to High-Sensitivity Cardiac Troponin-T and N-Terminal pro-B-Type Natriuretic Peptide in Older Adults (from the Atherosclerosis Risk in Communities Study).

Madan N, Lee AK, Matsushita K, Hoogeveen RC, Ballantyne CM, Selvin E, McEvoy JW.

Am J Cardiol. 2019 Jul 15;124(2):245-252. doi: 10.1016/j.amjcard.2019.04.030. Epub 2019 Apr 23.

PMID:
31088661
21.

High-sensitivity Cardiac Troponin and Natriuretic Peptide in Persons Without Cardiovascular Disease and Subsequent Risk of Infection: Atherosclerosis Risk in Communities Study.

Ishigami J, Hoogeveen RC, Ballantyne CM, Folsom AR, Coresh J, Selvin E, Matsushita K.

Am J Epidemiol. 2019 May 7. pii: kwz113. doi: 10.1093/aje/kwz113. [Epub ahead of print]

PMID:
31063194
22.

Poststatin Lipid Therapeutics: A Review.

Jia X, Lorenz P, Ballantyne CM.

Methodist Debakey Cardiovasc J. 2019 Jan-Mar;15(1):32-38. doi: 10.14797/mdcj-15-1-32. Review.

23.

ApoB, small-dense LDL-C, Lp(a), LpPLA2 activity, and cognitive change.

Pokharel Y, Mouhanna F, Nambi V, Virani SS, Hoogeveen R, Alonso A, Heiss G, Coresh J, Mosley T, Gottesman RF, Ballantyne CM, Power MC.

Neurology. 2019 May 28;92(22):e2580-e2593. doi: 10.1212/WNL.0000000000007574. Epub 2019 May 1.

PMID:
31043469
24.

High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study.

Jia X, Sun W, Hoogeveen RC, Nambi V, Matsushita K, Folsom AR, Heiss G, Couper DJ, Solomon SD, Boerwinkle E, Shah A, Selvin E, de Lemos JA, Ballantyne CM.

Circulation. 2019 Jun 4;139(23):2642-2653. doi: 10.1161/CIRCULATIONAHA.118.038772. Epub 2019 Apr 29.

PMID:
31030544
25.
26.

Facility-Level Variation in Stress Test Utilization in Veterans With Ischemic Heart Disease.

Shah NR, Ahmed ST, Winchester DE, Ramsey DJ, Akeroyd JM, Wu WC, Waldo SW, Schofield RS, Ballantyne CM, Petersen LA, Virani SS.

JACC Cardiovasc Imaging. 2019 Jul;12(7 Pt 1):1292-1293. doi: 10.1016/j.jcmg.2019.02.020. Epub 2019 Apr 17. No abstract available.

PMID:
31005521
27.

Cancer Survivorship and Subclinical Myocardial Damage: The Atherosclerosis Risk in Communities (ARIC) Study.

Florido R, Lee AK, McEvoy JW, Hoogeveen RC, Koton S, Vitolins MZ, Shenoy C, Russell SD, Blumenthal RS, Ndumele CE, Ballantyne CM, Joshu CE, Platz EA, Selvin E.

Am J Epidemiol. 2019 Mar 30. pii: kwz088. doi: 10.1093/aje/kwz088. [Epub ahead of print]

PMID:
30927355
28.

Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.

Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Gregson J, Pocock SJ, Ballantyne CM; REDUCE-IT Investigators.

J Am Coll Cardiol. 2019 Jun 11;73(22):2791-2802. doi: 10.1016/j.jacc.2019.02.032. Epub 2019 Mar 18.

29.

Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events.

Patel RS, Schmidt AF, Tragante V, McCubrey RO, Holmes MV, Howe LJ, Direk K, Åkerblom A, Leander K, Virani SS, Kaminski KA, Muehlschlegel JD, Dubé MP, Allayee H, Almgren P, Alver M, Baranova EV, Behlouli H, Boeckx B, Braund PS, Breitling LP, Delgado G, Duarte NE, Dufresne L, Eriksson N, Foco L, Gijsberts CM, Gong Y, Hartiala J, Heydarpour M, Hubacek JA, Kleber M, Kofink D, Kuukasjärvi P, Lee VV, Leiherer A, Lenzini PA, Levin D, Lyytikäinen LP, Martinelli N, Mons U, Nelson CP, Nikus K, Pilbrow AP, Ploski R, Sun YV, Tanck MWT, Tang WHW, Trompet S, van der Laan SW, van Setten J, Vilmundarson RO, Viviani Anselmi C, Vlachopoulou E, Boerwinkle E, Briguori C, Carlquist JF, Carruthers KF, Casu G, Deanfield J, Deloukas P, Dudbridge F, Fitzpatrick N, Gigante B, James S, Lokki ML, Lotufo PA, Marziliano N, Mordi IR, Muhlestein JB, Newton Cheh C, Pitha J, Saely CH, Samman-Tahhan A, Sandesara PB, Teren A, Timmis A, Van de Werf F, Wauters E, Wilde AAM, Ford I, Stott DJ, Algra A, Andreassi MG, Ardissino D, Arsenault BJ, Ballantyne CM, Bergmeijer TO, Bezzina CR, Body SC, Bogaty P, de Borst GJ, Brenner H, Burkhardt R, Carpeggiani C, Condorelli G, Cooper-DeHoff RM, Cresci S, de Faire U, Doughty RN, Drexel H, Engert JC, Fox KAA, Girelli D, Hagström E, Hazen SL, Held C, Hemingway H, Hoefer IE, Hovingh GK, Johnson JA, de Jong PA, Jukema JW, Kaczor MP, Kähönen M, Kettner J, Kiliszek M, Klungel OH, Lagerqvist B, Lambrechts D, Laurikka JO, Lehtimäki T, Lindholm D, Mahmoodi BK, Maitland-van der Zee AH, McPherson R, Melander O, Metspalu A, Pepinski W, Olivieri O, Opolski G, Palmer CN, Pasterkamp G, Pepine CJ, Pereira AC, Pilote L, Quyyumi AA, Richards AM, Sanak M, Scholz M, Siegbahn A, Sinisalo J, Smith JG, Spertus JA, Stewart AFR, Szczeklik W, Szpakowicz A, Ten Berg JM, Thanassoulis G, Thiery J, van der Graaf Y, Visseren FLJ, Waltenberger J; CARDIoGRAMPlusC4D Consortium, Van der Harst P, Tardif JC, Sattar N, Lang CC, Pare G, Brophy JM, Anderson JL, März W, Wallentin L, Cameron VA, Horne BD, Samani NJ, Hingorani AD, Asselbergs FW.

Circ Genom Precis Med. 2019 Apr;12(4):e002471. doi: 10.1161/CIRCGEN.119.002471. Epub 2019 Mar 21.

PMID:
30897348
30.

Subsequent Event Risk in Individuals With Established Coronary Heart Disease.

Patel RS, Tragante V, Schmidt AF, McCubrey RO, Holmes MV, Howe LJ, Direk K, Åkerblom A, Leander K, Virani SS, Kaminski KA, Muehlschlegel JD, Allayee H, Almgren P, Alver M, Baranova EV, Behloui H, Boeckx B, Braund PS, Breitling LP, Delgado G, Duarte NE, Dubé MP, Dufresne L, Eriksson N, Foco L, Scholz M, Gijsberts CM, Glinge C, Gong Y, Hartiala J, Heydarpour M, Hubacek JA, Kleber M, Kofink D, Kotti S, Kuukasjärvi P, Lee VV, Leiherer A, Lenzini PA, Levin D, Lyytikäinen LP, Martinelli N, Mons U, Nelson CP, Nikus K, Pilbrow AP, Ploski R, Sun YV, Tanck MWT, Tang WHW, Trompet S, van der Laan SW, Van Setten J, Vilmundarson RO, Viviani Anselmi C, Vlachopoulou E, Al Ali L, Boerwinkle E, Briguori C, Carlquist JF, Carruthers KF, Casu G, Deanfield J, Deloukas P, Dudbridge F, Engstrøm T, Fitzpatrick N, Fox K, Gigante B, James S, Lokki ML, Lotufo PA, Marziliano N, Mordi IR, Muhlestein JB, Newton-Cheh C, Pitha J, Saely CH, Samman-Tahhan A, Sandesara PB, Teren A, Timmis A, Van de Werf F, Wauters E, Wilde AAM, Ford I, Stott DJ, Algra A, Andreassi MG, Ardissino D, Arsenault BJ, Ballantyne CM, Bergmeijer TO, Bezzina CR, Body SC, Boersma EH, Bogaty P, Bots ML, Brenner H, Brugts JJ, Burkhardt R, Carpeggiani C, Condorelli G, Cooper-DeHoff RM, Cresci S, Danchin N, de Faire U, Doughty RN, Drexel H, Engert JC, Fox KAA, Girelli D, Grobbee DE, Hagström E, Hazen SL, Held C, Hemingway H, Hoefer IE, Hovingh GK, Jabbari R, Johnson JA, Jukema JW, Kaczor MP, Kähönen M, Kettner J, Kiliszek M, Klungel OH, Lagerqvist B, Lambrechts D, Laurikka JO, Lehtimäki T, Lindholm D, Mahmoodi BK, Maitland-van der Zee AH, McPherson R, Melander O, Metspalu A, Niemcunowicz-Janica A, Olivieri O, Opolski G, Palmer CN, Pasterkamp G, Pepine CJ, Pereira AC, Pilote L, Quyyumi AA, Richards AM, Sanak M, Siegbahn A, Simon T, Sinisalo J, Smith JG, Spertus JA, Stender S, Stewart AFR, Szczeklik W, Szpakowicz A, Tardif JC, Ten Berg JM, Tfelt-Hansen J, Thanassoulis G, Thiery J, Torp-Pedersen C, van der Graaf Y, Visseren FLJ, Waltenberger J, Weeke PE, Van der Harst P, Lang CC, Sattar N, Cameron VA, Anderson JL, Brophy JM, Pare G, Horne BD, März W, Wallentin L, Samani NJ, Hingorani AD, Asselbergs FW.

Circ Genom Precis Med. 2019 Apr;12(4):e002470. doi: 10.1161/CIRCGEN.119.002470. Epub 2019 Mar 21.

PMID:
30896328
31.

Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.

Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, Robinson PL, Ballantyne CM; CLEAR Harmony Trial.

N Engl J Med. 2019 Mar 14;380(11):1022-1032. doi: 10.1056/NEJMoa1803917.

32.

Eligibility and Cost for Icosapent Ethyl Based on the REDUCE-IT Trial.

Jia X, Akeroyd JM, Nasir K, Nambi V, Ballantyne CM, Petersen LA, Virani SS.

Circulation. 2019 Mar 5;139(10):1341-1343. doi: 10.1161/CIRCULATIONAHA.118.038691. No abstract available.

PMID:
30865483
33.

Central and peripheral pulse wave velocity and subclinical myocardial stress and damage in older adults.

Liu S, Kim ED, Wu A, Meyer ML, Cheng S, Hoogeveen RC, Ballantyne CM, Tanaka H, Heiss G, Selvin E, Matsushita K.

PLoS One. 2019 Feb 27;14(2):e0212892. doi: 10.1371/journal.pone.0212892. eCollection 2019.

34.

Icosapent Ethyl Effects on Fatty Acid Profiles in Statin-Treated Patients With High Triglycerides: The Randomized, Placebo-controlled ANCHOR Study.

Ballantyne CM, Manku MS, Bays HE, Philip S, Granowitz C, Doyle RT Jr, Juliano RA.

Cardiol Ther. 2019 Jun;8(1):79-90. doi: 10.1007/s40119-019-0131-8. Epub 2019 Feb 20.

35.

Sleep apnea and galectin-3: possible sex-specific relationship.

Singh M, Hanis CL, Redline S, Ballantyne CM, Hamzeh I, Aguilar D.

Sleep Breath. 2019 Feb 5. doi: 10.1007/s11325-019-01788-5. [Epub ahead of print]

PMID:
30721387
36.

Lipoprotein(a) levels and risk of cardiovascular disease events in individuals with diabetes mellitus or prediabetes: The Atherosclerosis Risk in Communities study.

Saeed A, Sun W, Agarwala A, Virani SS, Nambi V, Coresh J, Selvin E, Boerwinkle E, Jones PH, Ballantyne CM, Hoogeveen RC.

Atherosclerosis. 2019 Mar;282:52-56. doi: 10.1016/j.atherosclerosis.2018.12.022. Epub 2018 Dec 30.

PMID:
30685442
37.

Association of Body Mass Index With Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Cardiovascular Disease.

Hira RS, Kataruka A, Akeroyd JM, Ramsey DJ, Pokharel Y, Gurm HS, Nasir K, Deswal A, Jneid H, Alam M, Ballantyne CM, Petersen LA, Virani SS.

Circ Cardiovasc Qual Outcomes. 2019 Jan;12(1):e004817. doi: 10.1161/CIRCOUTCOMES.118.004817.

PMID:
30636483
38.

Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial.

Virani SS, Akeroyd JM, Nambi V, Michos ED, Morris PB, Nasir K, Smith SC Jr, Stone NJ, Petersen LA, Ballantyne CM.

Circulation. 2019 Jan 15;139(3):410-412. doi: 10.1161/CIRCULATIONAHA.118.034993. No abstract available.

PMID:
30586689
39.

Low-Density Lipoprotein Cholesterol: Is 160 the New 190?

Virani SS, Ballantyne CM.

Circulation. 2018 Nov 20;138(21):2326-2329. doi: 10.1161/CIRCULATIONAHA.118.034922. No abstract available.

PMID:
30571588
40.

Association of Cardiac Injury and Malignant Left Ventricular Hypertrophy With Risk of Heart Failure in African Americans: The Jackson Heart Study.

Pandey A, Keshvani N, Ayers C, Correa A, Drazner MH, Lewis A, Rodriguez CJ, Hall ME, Fox ER, Mentz RJ, deFilippi C, Seliger SL, Ballantyne CM, Neeland IJ, de Lemos JA, Berry JD.

JAMA Cardiol. 2019 Jan 1;4(1):51-58. doi: 10.1001/jamacardio.2018.4300.

PMID:
30566191
41.

Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia.

Reeskamp LF, Kastelein JJP, Moriarty PM, Duell PB, Catapano AL, Santos RD, Ballantyne CM.

Atherosclerosis. 2019 Jan;280:109-117. doi: 10.1016/j.atherosclerosis.2018.11.017. Epub 2018 Nov 10.

PMID:
30500603
42.

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.

Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM; REDUCE-IT Investigators.

N Engl J Med. 2019 Jan 3;380(1):11-22. doi: 10.1056/NEJMoa1812792. Epub 2018 Nov 10.

PMID:
30415628
43.

Genome Analyses of >200,000 Individuals Identify 58 Loci for Chronic Inflammation and Highlight Pathways that Link Inflammation and Complex Disorders.

Ligthart S, Vaez A, Võsa U, Stathopoulou MG, de Vries PS, Prins BP, Van der Most PJ, Tanaka T, Naderi E, Rose LM, Wu Y, Karlsson R, Barbalic M, Lin H, Pool R, Zhu G, Macé A, Sidore C, Trompet S, Mangino M, Sabater-Lleal M, Kemp JP, Abbasi A, Kacprowski T, Verweij N, Smith AV, Huang T, Marzi C, Feitosa MF, Lohman KK, Kleber ME, Milaneschi Y, Mueller C, Huq M, Vlachopoulou E, Lyytikäinen LP, Oldmeadow C, Deelen J, Perola M, Zhao JH, Feenstra B; LifeLines Cohort Study, Amini M; CHARGE Inflammation Working Group, Lahti J, Schraut KE, Fornage M, Suktitipat B, Chen WM, Li X, Nutile T, Malerba G, Luan J, Bak T, Schork N, Del Greco M F, Thiering E, Mahajan A, Marioni RE, Mihailov E, Eriksson J, Ozel AB, Zhang W, Nethander M, Cheng YC, Aslibekyan S, Ang W, Gandin I, Yengo L, Portas L, Kooperberg C, Hofer E, Rajan KB, Schurmann C, den Hollander W, Ahluwalia TS, Zhao J, Draisma HHM, Ford I, Timpson N, Teumer A, Huang H, Wahl S, Liu Y, Huang J, Uh HW, Geller F, Joshi PK, Yanek LR, Trabetti E, Lehne B, Vozzi D, Verbanck M, Biino G, Saba Y, Meulenbelt I, O'Connell JR, Laakso M, Giulianini F, Magnusson PKE, Ballantyne CM, Hottenga JJ, Montgomery GW, Rivadineira F, Rueedi R, Steri M, Herzig KH, Stott DJ, Menni C, Frånberg M, St Pourcain B, Felix SB, Pers TH, Bakker SJL, Kraft P, Peters A, Vaidya D, Delgado G, Smit JH, Großmann V, Sinisalo J, Seppälä I, Williams SR, Holliday EG, Moed M, Langenberg C, Räikkönen K, Ding J, Campbell H, Sale MM, Chen YI, James AL, Ruggiero D, Soranzo N, Hartman CA, Smith EN, Berenson GS, Fuchsberger C, Hernandez D, Tiesler CMT, Giedraitis V, Liewald D, Fischer K, Mellström D, Larsson A, Wang Y, Scott WR, Lorentzon M, Beilby J, Ryan KA, Pennell CE, Vuckovic D, Balkau B, Concas MP, Schmidt R, Mendes de Leon CF, Bottinger EP, Kloppenburg M, Paternoster L, Boehnke M, Musk AW, Willemsen G, Evans DM, Madden PAF, Kähönen M, Kutalik Z, Zoledziewska M, Karhunen V, Kritchevsky SB, Sattar N, Lachance G, Clarke R, Harris TB, Raitakari OT, Attia JR, van Heemst D, Kajantie E, Sorice R, Gambaro G, Scott RA, Hicks AA, Ferrucci L, Standl M, Lindgren CM, Starr JM, Karlsson M, Lind L, Li JZ, Chambers JC, Mori TA, de Geus EJCN, Heath AC, Martin NG, Auvinen J, Buckley BM, de Craen AJM, Waldenberger M, Strauch K, Meitinger T, Scott RJ, McEvoy M, Beekman M, Bombieri C, Ridker PM, Mohlke KL, Pedersen NL, Morrison AC, Boomsma DI, Whitfield JB, Strachan DP, Hofman A, Vollenweider P, Cucca F, Jarvelin MR, Jukema JW, Spector TD, Hamsten A, Zeller T, Uitterlinden AG, Nauck M, Gudnason V, Qi L, Grallert H, Borecki IB, Rotter JI, März W, Wild PS, Lokki ML, Boyle M, Salomaa V, Melbye M, Eriksson JG, Wilson JF, Penninx BWJH, Becker DM, Worrall BB, Gibson G, Krauss RM, Ciullo M, Zaza G, Wareham NJ, Oldehinkel AJ, Palmer LJ, Murray SS, Pramstaller PP, Bandinelli S, Heinrich J, Ingelsson E, Deary IJ, Mägi R, Vandenput L, van der Harst P, Desch KC, Kooner JS, Ohlsson C, Hayward C, Lehtimäki T, Shuldiner AR, Arnett DK, Beilin LJ, Robino A, Froguel P, Pirastu M, Jess T, Koenig W, Loos RJF, Evans DA, Schmidt H, Smith GD, Slagboom PE, Eiriksdottir G, Morris AP, Psaty BM, Tracy RP, Nolte IM, Boerwinkle E, Visvikis-Siest S, Reiner AP, Gross M, Bis JC, Franke L, Franco OH, Benjamin EJ, Chasman DI, Dupuis J, Snieder H, Dehghan A, Alizadeh BZ.

Am J Hum Genet. 2018 Nov 1;103(5):691-706. doi: 10.1016/j.ajhg.2018.09.009.

44.

Effect of Evolocumab on Coronary Plaque Composition.

Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJP, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Honda S, Shishikura D, Scherer DJ, Borgman M, Brennan DM, Wolski K, Nissen SE.

J Am Coll Cardiol. 2018 Oct 23;72(17):2012-2021. doi: 10.1016/j.jacc.2018.06.078.

PMID:
30336824
45.

Case reports of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition nonresponse.

Saeed A, Virani SS, Jones PH, Ballantyne CM, Nambi V.

J Clin Lipidol. 2018 Sep - Oct;12(5):1141-1145. doi: 10.1016/j.jacl.2018.05.017. Epub 2018 Jun 1.

PMID:
30318064
46.

WITHDRAWN: Raising the Bar by Lowering the Target: Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management.

Ballantyne CM, Bhatt DL, Cannon CP, Fazio S, Sabatine MS.

Am J Cardiol. 2018 Aug 16. pii: S0002-9149(18)31653-9. doi: 10.1016/j.amjcard.2018.08.020. [Epub ahead of print] No abstract available.

PMID:
30301542
47.

Prospective Study of Endogenous Hormones and Incidence of Venous Thromboembolism: The Atherosclerosis Risk in Communities Study.

Roetker NS, MacLehose RF, Hoogeveen RC, Ballantyne CM, Basu S, Cushman M, Folsom AR.

Thromb Haemost. 2018 Nov;118(11):1940-1950. doi: 10.1055/s-0038-1673613. Epub 2018 Oct 8.

PMID:
30296818
48.

Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial.

Nicholls SJ, Lincoff AM, Bash D, Ballantyne CM, Barter PJ, Davidson MH, Kastelein JJP, Koenig W, McGuire DK, Mozaffarian D, Pedersen TR, Ridker PM, Ray K, Karlson BW, Lundström T, Wolski K, Nissen SE.

Clin Cardiol. 2018 Oct;41(10):1281-1288. doi: 10.1002/clc.23055. Epub 2018 Sep 28. Review.

49.

Are All Benefits and Harms Equal?

Saeed A, Virani SS, Ballantyne CM, Taylor AA, Nambi V.

J Am Coll Cardiol. 2018 Aug 14;72(7):819-820. doi: 10.1016/j.jacc.2018.05.055. No abstract available.

50.

Diagnostic Performance of 1,5-Anhydroglucitol Compared to 2-H Glucose in the Atherosclerosis Risk in Communities Study.

Warren B, Lee AK, Ballantyne CM, Hoogeveen RC, Pankow JS, Grams M, Köttgen A, Selvin E.

Clin Chem. 2018 Oct;64(10):1536-1537. doi: 10.1373/clinchem.2018.291773. Epub 2018 Aug 7. No abstract available.

Supplemental Content

Loading ...
Support Center